

Costs, quality-adjusted life years, and value-of-information of different thresholds for the initiation of invasive ventilation in hypoxemic respiratory failure

Yarnell, Christopher J MD; ORCID 0000-0001-5657-9398

Barrett, Kali; ORCID 0000-0001-7147-2222

Heath, Anna; PhD; ORCID 0000-0002-7263-4251

Herridge, Margaret S. MSc MD MPH

Fowler, Rob MD MSc

Sung, Lillian MD PhD

Naimark, David M MSc MD; ORCID 0000-0002-0621-0637

Tomlinson, George PhD

2022-03-02

Abstract: 255 words

Text: 3096 words (including headers)

Author details

Affiliations

- Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada (CJY, KB, MH, RAF)
- Department of Medicine, Division of Respiriology, University Health Network and Sinai Health System, Toronto, Canada (CJY, KB, MH)
- Department of Medicine, University of Toronto, Toronto, Canada (MH, DN, RAF)
- Department of Medicine, University Health Network and Sinai Health System, Toronto, Canada (GT, MH)
- Institute for Clinical Evaluative Sciences, Toronto, Canada (RAF)
- Institute of Health Policy, Management and Evaluation, University of Toronto, Canada (CJY, KB, DN, RAF, LS, GT, MH)
- Sunnybrook Health Sciences Centre, Toronto, Canada (DN, RAF)
- Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada (LS)
- Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Canada (AH)
- Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Canada (AH)
- Department of Statistical Science, University College London, London, UK (AH)

Contributions

- Concept: CJY, DN, GT
- Design: CJY, AH, KB, DN, RAF, LS, GT
- Data analysis and interpretation: All
- Data acquisition: CJY
- Drafting, revising for important intellectual content, final approval, and agreement to be accountable: all

Corresponding author

Christopher Yarnell

Medical-Surgical ICU, 10th floor

585 University Avenue, Toronto, ON, Canada, M5G 1X5

christopher.yarnell@uhn.ca

Declarations of conflicts of interest

No conflicts

Funding and role of funders in study

Dr Yarnell was funded by the Canadian Institutes for Health Research Vanier Scholar program, the Eliot Phillipson Clinician Scientist Training Program, and the Clinician Investigator Program of the University of Toronto. Dr Heath is supported by a Canada Research Chair in Statistical Trial Design and funded by the Discovery Grant Program of the Natural Sciences and Engineering Research Council of Canada (RGPIN-2021-03366). Dr Sung is supported by the Canada Research Chair in Pediatric Oncology Supportive Care. Dr Fowler is the H. Barrie Fairley Professor of Critical Care at the University Health Network, Interdepartmental Division of Critical Care Medicine, University of Toronto. Funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; nor in the decision to submit the manuscript for publication. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by any of the funding agencies is intended or should be inferred.

Acknowledgements

We thank the following for helpful comments: Allan Detsky.

Abstract

Objective: To estimate costs, quality-adjusted life-years, and the value of undertaking a future randomized controlled trial for different oxygenation thresholds used to initiate invasive ventilation in hypoxemic respiratory failure.

Design: Model-based cost-utility estimation with individual-level simulation and value-of-information analysis.

Setting: Critical care units.

Participants: Adults admitted to critical care receiving non-invasive oxygen.

Interventions: We compared four strategies: initiation of invasive ventilation at thresholds of saturation-to-inspired oxygen fraction ratio (SF) < 110, < 98, or < 88, and usual care.

Main results: An invasive ventilation initiation threshold of SF < 110, compared to usual care, resulted in more predicted invasive ventilation (62% vs 31%), hospital survival (78.4% vs 75.5%), quality-adjusted life years (QALYs) (8.48 vs 8.34), and lifetime costs (86,700 Canadian dollars (CAD) vs 75,600 CAD). Among the four strategies, threshold SF < 110 had the highest expected net monetary benefit (761,000 CAD), but there was significant uncertainty, because all four strategies had similar probability (range: 23.5% to 27.5%) of having the best net monetary benefit. The expected value to society over the next 10 years of a 400-person randomized trial of oxygenation thresholds was 4.27 billion CAD, and remained high (2.64 billion CAD) in a scenario analysis considering a hypothetical threshold that resulted in less invasive ventilation and similar survival compared to usual care.

Conclusion: The preferred threshold to initiate invasive ventilation in hypoxemic respiratory failure is uncertain. It would be highly valuable to society to identify thresholds that, in comparison to usual care, either improve survival or reduce invasive ventilation without reducing survival.

Key points

Question: What are the costs and quality-adjusted life-years associated with different oxygenation thresholds for initiating invasive ventilation, and what is the expected value to society of a randomized controlled trial?

Findings: In this health economic evaluation comparing usual care to three different thresholds for initiating invasive ventilation in hypoxemic respiratory failure based on the saturation-to-inspired oxygen fraction ratio (SF), we found that threshold SF < 110 had the highest expected quality-adjusted life-years and net monetary benefit, despite increased predicted invasive ventilation use. However, there was significant residual uncertainty, and the expected value to society of a 400-person randomized trial to compare thresholds for initiating invasive ventilation was greater than 2.5 billion Canadian dollars.

Meaning: The preferred threshold to initiate invasive ventilation in hypoxemic respiratory failure is uncertain and further study would be valuable to society.

Social media summary (280 characters)

When should we intubate and start invasive ventilation for people with hypoxemic respiratory failure? Our health economic evaluation shows that the preferred threshold is uncertain, but that a clinical trial to determine such a threshold would be immensely valuable to patients and society

1 **Introduction**

2 Acute hypoxemic respiratory failure comprises at least 10% of admissions to intensive care
3 units (ICUs) worldwide, is associated with ICU mortality of 25-40%, and can cause long-term
4 functional impairment in survivors.(1–4) Invasive ventilation is a potentially life-saving therapy
5 instituted in severe cases, but it can lead to adverse events, including periprocedural cardiac
6 arrest(5,6), ventilator-associated pneumonia, delirium, and ICU-acquired weakness.(7–9) The
7 clinical decision to initiate invasive ventilation is based on expert opinion and clinical
8 experience, with little data available to identify people who truly benefit. However, recent
9 research has suggested that initiating invasive ventilation at less severe hypoxemia in
10 populations with high baseline mortality risk, which would increase the use of invasive
11 ventilation, may improve 28-day survival.(10,11)

12 The provision of invasive ventilation is resource-intensive.(12–14) Prior efforts to study the
13 cost-effectiveness of invasive ventilation have focused on adjunct therapies such as ventilator
14 management, proning, pulmonary artery catheters, or extracorporeal membrane oxygenation
15 (ECMO).(12,14–18) The resource consequences of adopting different oxygenation thresholds to
16 trigger invasive ventilation have not been estimated. The economic value to society of a
17 randomized trial of thresholds for initiating invasive ventilation is also unknown.

18 In order to clarify the tradeoffs between short-term mortality, long-term disability, and
19 resource use; and to help quantify the potential economic value of a randomized controlled
20 trial on this topic; we performed a cost-utility and value-of-information analysis comparing
21 usual care to three different oxygenation thresholds for the initiation of invasive ventilation.

22 **Methods**

23 We performed a model-based cost-utility and value-of-information analysis comparing usual
24 care and three different proposed oxygenation thresholds for initiation of invasive ventilation
25 for people with acute hypoxemic respiratory failure. We adopted the perspective of the publicly
26 funded healthcare payer, a lifetime horizon, and discounted future outcomes by 1.5% annually.
27 We followed the Consolidated Health Economic Evaluation Reporting Standards (checklist in
28 Supplement), and recommendations from the Canadian Agency for Drugs and Technologies in
29 Health.(13,19–21) All analysis code is available at <https://doi.org/10.5281/zenodo.7603995>.

30 **Reference case**

31 The reference case was an adult at admission to ICU with non-COVID acute hypoxemic
32 respiratory failure, receiving oxygen via high-flow nasal cannula, non-rebreather mask, or non-
33 invasive positive pressure ventilation.

34 **Strategies**

35 In the primary scenario we compared four strategies: usual care and initiation of invasive
36 ventilation when saturation-to-inspired oxygen fraction ratio (SF) fell below 110, 98, or 88.
37 Lower SF values indicate more severe hypoxemia. The SF ratio is an attractive choice for
38 threshold definition because it is a simple yet accurate measure of hypoxemia applicable to
39 acute care settings worldwide. It can be measured without blood sampling.(22,23)
40 Clinically, the three target values correspond to steeper parts of the oxyhemoglobin
41 dissociation curve at high inspired oxygen fractions. Using a non-linear formula to impute
42 arterial-to-inspired oxygen ratios (PF), SF 88, 98, and 110 correspond to PF of at least 55, 68,

43 and 85 mmHg.(24,25) These thresholds have been recently evaluated in an observational study
44 that provides estimates of 28-day invasive ventilation rates and survival for each threshold.(11)
45 We also included a “usual care” strategy, where invasive ventilation occurred at clinical
46 discretion without the use of specified thresholds.

47 Model structure and outputs

48 We built an individual-level simulation model to describe critical illness (Figure 1). We used
49 two-dimensional Monte Carlo simulation to understand how uncertainty affects the model
50 outputs, first sampling model input parameters (such as the probability of hospital survival)
51 1000 times from their respective distributions (2nd order Monte Carlo), and then simulating the
52 clinical course of 1000 individuals from oxygen therapy through to death (1st order Monte
53 Carlo) for each set of 2nd order samples.

54 Model outputs included clinical outcomes and costs averaged over both 1st and 2nd order
55 iterations. The primary clinical outcome was quality-adjusted life expectancy denominated in
56 years (QALYs). Secondary clinical outcomes were hospital survival, life-years, receipt and
57 duration of invasive ventilation, duration of non-invasive oxygen therapy in ICU, duration of
58 hospital stay after ICU discharge, and incidence of long-term disability. Costs included the cost
59 of intensive care with and without invasive ventilation, ongoing hospitalization after ICU
60 discharge, and ongoing health care during the rest of a survivor’s life post-discharge. Costs were
61 denominated in 2022 Canadian dollars.

62 Key assumptions

63 All people were cared for in an intensive care unit. Invasive ventilation availability for
64 individuals was unaffected by invasive ventilation use in others, approximating usual critical
65 care, as opposed to care during pandemic surges where human and ventilator resources may
66 be scarce.(26–28) We assumed no deviation from thresholds, no re-initiation of invasive
67 ventilation, no ICU readmission, and no utility during hospitalization. Societal willingness-to-pay
68 (WTP) was set at an incremental 100,000 Canadian dollars per QALY gained.(19,29)

69 Data sources and parameters

70 We performed a literature search for each parameter. We favored recent estimates specific to
71 the North American or Northern European context (Tables e2, e3, e4, e5).

72 Participant characteristics

73 The distribution of participant sex and age were based on a cohort of people similar to the
74 reference patient from the Medical Information Mart for Intensive Care version IV (MIMIC-IV)
75 database of 76,540 ICU admissions to an academic hospital in the USA.(30,31)

76 Clinical events

77 For each individual, we first simulated hospital survival according to threshold and then
78 simulated whether invasive ventilation occurred conditional on survival and threshold. The
79 probabilities of invasive ventilation and hospital survival followed a beta distribution with mean
80 event probability based on an observational study of oxygenation thresholds for initiating
81 invasive ventilation.(11) Although the study estimated 28-day outcomes, we used these
82 estimates for hospital outcomes because more comprehensive estimates were not available.

83 We increased the standard deviation in the estimates from the observational study 5-fold from
84 0.02 to 0.1, because the data came from a single center. This was analogous to a 25-fold
85 decrease in sample size, meaning that we treated the estimate from the 3,357-person
86 observational study as if it provided as much information as a randomized trial enrolling
87 approximately 134 people.(32)

88 Hospital survivors had the remainder of their lifespan drawn from a Weibull distribution based
89 on a cohort of intensive care unit survivors with 5 years of follow-up, in order to incorporate
90 the increased time-varying risk of death faced by survivors of critical illness (Figure e1).(4)

91 We used time-to-event models to simulate durations of invasive ventilation, ICU stay while not
92 invasively ventilated, and hospital stay after ICU discharge. We fit Weibull curves to the same
93 cohort that was used to derive the parameter estimates for invasive ventilation and hospital
94 survival. For the model describing duration of invasive ventilation, we included age, sex, and
95 survival as covariates; for duration of oxygen therapy and hospital stay we used the same
96 covariates with the addition of a binary covariate for receipt of invasive ventilation.(33,34)

97 The probability of long-term disability was based on a cohort of mechanical ventilation
98 survivors, which divided people into disability risk groups according to age, duration of
99 ventilation, and length of ICU stay.(35) In our model, survivors of mechanical ventilation were
100 divided into the same groups. The probability of long-term disability followed a beta
101 distribution, with mean probability within each group equal to the observed probability of
102 requiring assistance with bathing at 12-months.

103 Utilities

104 We used population-based estimates to estimate utility in survivors.(36) Survivors with long-
105 term disability incurred an ongoing disutility with mean 0.15, which was subtracted from their
106 population-based utility. This was based on prior work showing persistent decreased utility in
107 critical illness survivors out to at least five years.(4)

108 Costs

109 Costs accumulated during hospitalization and any subsequent recovery. To estimate daily ICU
110 cost while ventilated, ICU cost while not ventilated, and ward cost after ICU discharge, we
111 combined data from a study based in ICUs in Ottawa, Canada and a national survey of Canadian
112 ICUs.(37,38) We estimated mean annual costs for hospital survivors with data from a cohort of
113 acute respiratory distress syndrome survivors (3) and administrative data from Ontario,
114 Canada.(39) All costs were converted to CAD, adjusted for inflation, and reported in 2022
115 CAD.(40) Our model did not capture costs not covered by provincial health insurance, for
116 example, dental care, or outpatient medications for those under 65 years. We did not
117 incorporate economic losses due to underemployment of survivors or care partners.

118 Analysis

119 We compared strategies using the net monetary benefit, defined as $QALYS \times WTP - costs$. We
120 reported the incremental cost-utility ratio for non-dominated strategies relative to usual care.
121 We built the model in TreeAge Pro (v2021 R2) and analyzed outputs in R.(34,41) We reported
122 means and 95% credible intervals (CrI). We showed, for each strategy and at WTP ranging from
123 0 to 200,000 CAD, the probability of having the highest net monetary benefit.

124 Value-of-information analysis

125 Uncertainty in model inputs leads to uncertainty in model outputs. Broad adoption of an
126 invasive ventilation initiation threshold based on the average model output may be the best
127 decision using current knowledge. However, collecting additional information through a
128 randomized controlled trial may reveal that the current best decision is incorrect.

129 The economic consequence of an incorrect decision is referred to as the opportunity-cost.

130 Value-of-information analysis quantifies the opportunity-cost of deciding now, with imperfect
131 information, compared to an alternative decision once more information is available.(42) We
132 can compare the net monetary benefits of a decision made with perfect information (no
133 uncertainty in model parameters) and a decision made with current, imperfect information. The
134 difference is termed the expected value of perfect information (EVPI). Complete certainty for all
135 input parameters is unrealistic, so we also consider the value of perfect information in a subset
136 of input parameters, called the expected value of partial perfect information (EVPPI). However,
137 a randomized trial cannot provide complete certainty, at best it can reduce uncertainty. The
138 economic value of this reduction is the expected value of sample information (EVS).(43) The
139 EVSI can be calculated for different sample sizes.

140 We calculated EVPI, EVPPI, and EVSI for a proposed randomized controlled trial. We used the
141 Sheffield value-of-information application for EVPI and EVPPI, and non-parametric regression
142 for EVSI.(44–46) For EVPPI, we included the parameters for invasive ventilation rate and
143 hospital survival probability according to initiation threshold. We calculated the EVSI for
144 randomized trials with sample sizes ranging from 100 to 3200 participants. We did not evaluate
145 EVSI for trials with less than 100 participants, which would be too small to effect any change in

146 clinical practice. We combined these results with the annual number of Canadian ICU
147 admissions (38) and incidence of acute respiratory failure (1) to calculate population EVSI.

148 Scenario analysis

149 We considered two scenarios. The first scenario is described above, where there exists a
150 threshold for the initiation of invasive ventilation associated with increased use of invasive
151 ventilation and improved survival compared to usual care. In the second scenario, we
152 compared a hypothetical threshold to usual care, where the hypothetical threshold had used
153 less invasive ventilation with equivalent survival compared to usual care. We repeated the
154 analysis to assess the expected value of sample information if we could identify thresholds that
155 reduced the use of invasive ventilation while maintaining equivalent survival.

156 Results

157 Clinical outcomes

158 Invasive ventilation ranged from 20.7% with threshold SF < 88 to 62.1% with threshold SF < 110
159 (Table 1). Hospital survival ranged from 73.8% with threshold SF < 88 to 78.4% with threshold
160 SF < 110. Among additional hospital outcomes, the mean durations of ICU admission while not
161 ventilated, ICU admission while ventilated, and ward stay after ICU discharge were similar
162 across strategies. Long-term disability varied from 4.6% with threshold SF < 88 to 11.4% with
163 threshold SF < 110.

164 There were small differences in life expectancy and QALYs across thresholds, and larger relative
165 differences in costs. The lowest mean lifetime costs were 71,500 CAD (SF < 88), while the
166 highest mean costs were 86,700 CAD (SF < 110).

167 Comparing strategies

168 At the prespecified willingness-to-pay of 100,000 CAD, mean net monetary benefit ranged from
169 748,000 CAD (SF < 88) to 761,000 CAD (SF < 110). Among the four strategies, threshold SF < 110
170 was most likely to have the highest net monetary benefit. However, each threshold's
171 probability of having the highest net monetary benefit was similar, indicating significant
172 residual uncertainty in the model outputs. Figure 2 shows the similarity between the
173 probabilities of each threshold having the highest net monetary benefit. The incremental cost-
174 utility ratio for each threshold when compared to usual care was 84,000 CAD per QALY for SF <
175 110, 154,000 CAD per QALY for SF < 98, and 27,500 per QALY for SF < 88.

176 Value-of-information

177 At a willingness-to-pay of 100,000 CAD, the EVPI per person was 104,700 CAD. EVPPI for the
178 randomized trial group of parameters was 100,300 CAD and captured almost all of the value of
179 perfect information. A randomized trial of 400 patients had EVSI of 91,333 CAD per person.
180 Using a national annual incidence of 5,000 eligible people per year (38), a discount rate of 1.5%,
181 and a 10-year horizon over which the information will be useful, population EVSI for a
182 randomized controlled trial of 400 participants was 4.27 billion CAD.

183 Scenario analysis

184 Recall that the second scenario considered a hypothetical threshold which used less invasive
185 ventilation and achieved similar survival compared to usual care. The probability of invasive
186 ventilation was reduced from 28% with usual care to 20% with the hypothetical threshold,
187 without a difference in survival (75%) (Table e6). The hypothetical threshold was most likely to
188 have the highest net monetary benefit up to a willingness-to-pay value of 100,000 CAD, after

189 which the net monetary benefit was equal (Figure e2). Per-person EVPI was 62,900 CAD and
190 per-person EVPPI of a randomized controlled trial was 60,200 CAD. EVSI of a randomized
191 controlled trial with 400 participants was 56,500 CAD, corresponding to a 10-year population
192 EVSI of 2.64 billion CAD. In Figure 3 we show the population EVSI associated with randomized
193 controlled trials of varying sample sizes for both scenarios.

194 Discussion

195 In this health economic evaluation comparing usual care to three different oxygenation
196 thresholds for initiating invasive ventilation in hypoxemic respiratory failure, we found that the
197 threshold SF < 110 had the highest expected net monetary benefit, despite increased predicted
198 resource use and long-term disability. However, the probabilities of each threshold having the
199 highest net monetary benefit among the four strategies were similar, meaning that there was
200 significant residual uncertainty. The expected value to Canadian society of a 400-person
201 randomized controlled trial, based on the potential improvement in QALYs and a willingness-to-
202 pay of 100,000 CAD per QALY, was 4.27 billion dollars. The expected value of such a trial
203 remained high (2.64 billion CAD), even if the best alternative to usual care was a threshold with
204 lower invasive ventilation and equivalent mortality. These findings suggest that there is
205 uncertainty about the preferred threshold for initiating invasive ventilation, and that further
206 research on this question would be immensely valuable for society.

207 The findings build on prior work by illustrating the net impact of survival, ventilator resource
208 use, and disability on cost-effectiveness, in the setting where increased invasive ventilation is
209 associated with improved survival.(47) The SF < 110 threshold had a higher net monetary

210 benefit than usual care, after combining the QALY impact of additional survivors (3% absolute
211 increase), increased invasive ventilation use (31% absolute increase), and increased long-term
212 disability (5% absolute increase). The increase in predicted long-term disability resulted from
213 increased predicted use of invasive ventilation, which shifted patients to higher long-term
214 disability risk groups. Prior work has investigated the mortality associated with particular
215 thresholds for invasive ventilation but has not incorporated functional outcomes or costs
216 (10,11,48). It is somewhat reassuring that small improvements in survival associated with
217 increased use of invasive ventilation can be cost-effective. However, individuals may vary in the
218 extent to which they value a life affected by weakness, dependence, and post-traumatic stress
219 disorder.(3) Further research needs to clarify what increase in long-term disability risk is
220 acceptable to people in this situation.

221 These results also offer insights applicable to respiratory pandemics or resource-constrained
222 settings, despite using data from before the coronavirus-19 pandemic (COVID-19) and assuming
223 critical care capability typical of developed nations. Settings where the availability of
224 technology, personnel, or funding is limited could be approximated by a lower willingness-to-
225 pay, and our results show that as willingness-to-pay declines, the advantages of the most
226 severe hypoxemia threshold (SF < 88) increase relative to other strategies. Our model did not
227 consider ICU capacity as a constraint, and we did not consider the impact of SF thresholds on
228 population-level ICU bed requirements. Future modelling considering health system capacity
229 requirements at different SF thresholds needs to be considered.

230 The expected value of a randomized trial over 10 years on this topic was more than 2.5 billion
231 CAD and far exceeded the cost of the proposed trial, in both scenarios. The median cost of a

232 clinical trial with more than 1000 participants testing a novel pharmaceutical agent is
233 approximately 70 million CAD.(49) Our EVSIs could be overestimated because the value
234 captured in the EVSI assumes that all clinicians will incorporate the study findings into their
235 decision-making.(18,50) However, our population EVSIs could also be underestimated because
236 they correspond only to Canada, even though similar benefits could accrue to eligible people all
237 over the world.

238 This work has additional limitations. It is a model-based evaluation and may not incorporate
239 enough nuance from clinical practice to be useful. Our results depend on many decisions made
240 in the course of model construction; different decisions may have led to different results.(51)
241 We did not include patient engagement. Our results are most applicable to a Canadian context.
242 The thresholds rely on oxygen saturation, which can be overestimated when measured with a
243 pulse oximeter in people with darker skin pigment.(52) Some of the costing data used was from
244 more than 10 years ago and may not reflect the costs of high-flow nasal cannula which have
245 become commonly used for non-intubated patients with hypoxemic respiratory failure.
246 However, a prior health economic analysis in the UK found that high-flow nasal cannula use,
247 compared to standard oxygen or non-invasive ventilation, was likely to be cost saving.(53) The
248 costing data from a prior ARDS cohort is also limited because it focused on a younger group of
249 patients.(3) Our results are also limited by parameter validity. In particular, the parameters did
250 not incorporate threshold-related mortality beyond 28 days, because of data limitations. We
251 also do not have information on whether the probability of long-term disability varies by
252 threshold choice, beyond the extent to which it is affected by the use of invasive ventilation.
253 We included parameter uncertainty to address these limitations.

254 **Conclusion**

255 The preferred threshold to initiate invasive ventilation in hypoxemic respiratory failure is
256 uncertain. It would be highly valuable to society to identify thresholds that, in comparison to
257 usual care, either improve survival or reduce invasive ventilation without reducing survival.

Table: Model outputs, primary analysis

	Mean (95% credible interval)			
	Usual care	SF < 110	SF < 98	SF < 88
Durations (Days)				
ICU, non-IMV duration	4.6 (3.37 to 6.26)	4.46 (3.23 to 6.11)	4.54 (3.3 to 6.21)	4.64 (3.34 to 6.35)
IMV duration (among ventilated people)	8.7 (5.79 to 12.7)	8.95 (6.19 to 12.7)	8.81 (5.96 to 12.8)	8.32 (5.55 to 12.2)
Ward duration	5.67 (4.26 to 7.68)	5.57 (4.07 to 7.57)	5.62 (4.09 to 7.73)	5.69 (4.23 to 7.63)
Hospital outcomes (%)				
Invasive ventilation	30.7 (15.5 to 48.6)	62.1 (42.5 to 80.2)	42.6 (25.9 to 60.5)	20.7 (7.5 to 38.1)
Survival	75.5 (53.4 to 91.7)	78.4 (55.1 to 94.5)	76.4 (55.2 to 92.6)	73.8 (53 to 90.5)
Long-term disability	6.34 (2.6 to 11.8)	11.4 (6.4 to 18)	8.23 (4 to 13.6)	4.62 (1.6 to 9.3)
Lifetime outcomes				
Life expectancy (years)	11 (7.24 to 14.5)	11.3 (7.58 to 14.7)	11.1 (7.35 to 14.2)	10.7 (7.15 to 14)
QALYs	8.34 (5.54 to 11)	8.48 (5.6 to 11.1)	8.37 (5.51 to 10.9)	8.19 (5.49 to 10.7)
Cost (1000's CAD)	75.6 (63.7 to 88.5)	86.7 (72 to 103)	79.6 (67.1 to 95.4)	71.5 (60.3 to 83.9)
Net monetary benefit (1000's CAD)	759 (480 to 1020)	761 (476 to 1020)	758 (472 to 1000)	748 (484 to 1000)
Comparative outcomes				
Probability of highest net monetary benefit	0.246	0.275	0.246	0.233
Incremental cost-utility ratio (CAD)	Reference	84,000	154,000	26,800

Caption: This table summarizes the model outputs with the mean and 95% credible interval for each strategy. IMV – invasive mechanical ventilation, QALYs – quality-adjusted life years, CAD = 2022 Canadian dollars. Net monetary benefit calculated using a willingness-to-pay of 100,000 CAD per QALY. Incremental cost-utility ratio calculated for each threshold compared to usual care.

Figures

Figure 1: Diagram of health economic model




Figure 1 caption: This diagram shows the model structure. An individual began on the left, at “Person with hypoxemic respiratory failure.” Each individual was simulated through each of the four strategies, with the same tree structure for each threshold (A). First, we simulated individuals’ hospital survival, then whether they received invasive ventilation. For survivors, we simulated whether they sustained long-term disability, and finally simulated the remaining life-expectancy after hospital discharge.

Figure 2: Cost-effectiveness acceptability curve




Figure 2 caption: This figure shows the proportion of iterations that each strategy has the highest net monetary benefit versus willingness to pay. SF < 88 is the optimal choice until a willingness-to-pay of approximately 50,000 CAD, after which there is uncertainty until SF < 110 emerges as the optimal choice for willingness-to-pay values greater than 65,000 CAD.

Figure 3: Population expected value of a randomized trial by sample size




Figure 3 caption: This figure shows the population expected value of sample information (EVSI, y-axis) for randomized trials of different total sizes (x-axis, logarithmic scale) for both scenario 1 (left) and scenario 2(right). The expected value of sample information captures the value of the additional information gleaned from a study of a particular size. The value comes from an improved probability of correctly identifying the most cost-effective strategy. The population EVSI is derived by multiplying the per-person EVSI by the annual incidence of eligible people in Canada (5000) and the duration of information relevance (10 years), discounting future benefits by 1.5% per year. For these values of the EVSI we used a willingness-to-pay of 100,000 CAD. Note that these values only describe value that accrues to the Canadian population. EVSI = expected value of sample information, CAD = 2022 Canadian dollars.

References

1. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. *JAMA*. 2016 Feb;315(8):788.
2. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute Respiratory Distress Syndrome. *JAMA*. 2012 Jun;307(23):2526–33.
3. Herridge MS, Tansey CM, Matté A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional Disability 5 Years after Acute Respiratory Distress Syndrome. *New England Journal of Medicine*. 2011 Apr;364(14):1293–304.
4. Cuthbertson BH, Roughton S, Jenkinson D, Maclennan G, Vale L. Quality of life in the five years after intensive care: a cohort study. *Critical care (London, England)*. 2010;14(1):R6.
5. Cook T, Woodall N, Frerk C. The NAP4 report: Major complications of airway management in the UK [Internet]. London, England: Royal College of Anaesthetists; 2011. Available from: <http://www.rcoa.ac.uk/index.asp?PageID=1089>
6. Russotto V, Myatra SN, Laffey JG, Tassistro E, Antolini L, Bauer P, et al. Intubation Practices and Adverse Peri-intubation Events in Critically Ill Patients From 29 Countries. *JAMA*. 2021 Mar 23;325(12):1164–72.
7. Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. *Critical Care Medicine*. 2018 Sep;46(9):e825–73.
8. Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review. *Intensive Care Med*. 2020;46(5):888–906.
9. Vanhorebeek I, Latronico N, Van den Berghe G. ICU-acquired weakness. *Intensive Care Med*. 2020;46(4):637–53.
10. Bellani G, Laffey JG, Pham T, Madotto F, Fan E, Brochard L, et al. Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome: Insights from the LUNG SAFE Study. *American Journal of Respiratory and Critical Care Medicine*. 2017 Jan;195(1):67–77.
11. Yarnell CJ, Angriman F, Ferreyro BL, Liu K, De Grooth HJ, Burry L, et al. Oxygenation thresholds for invasive ventilation in hypoxemic respiratory failure: a target trial emulation in two cohorts. *Critical Care*. 2023 Feb 22;27(1):67.
12. Noseworthy TW, Konopad E, Shustack A, Johnston R, Grace M. Cost accounting of adult intensive care: methods and human and capital inputs. *Crit Care Med*. 1996 Jul;24(7):1168–72.
13. Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research. *Am J Respir Crit Care Med*. 2002 Feb 15;165(4):540–50.

14. Byrick RJ, Mindorff C, McKEE L, Mudge B. Cost-effectiveness of intensive care for respiratory failure patients. *Critical Care Medicine*. 1980 Jun;8(6):332–7.
15. Hamel MB, Phillips RS, Davis RB, Teno J, Connors AF, Desbiens N, et al. Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome. *American Journal of Medicine*. 2000 Dec;109(8):614–20.
16. Barrett KA, Hawkins N, Fan E. Economic Evaluation of Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. *Crit Care Med*. 2019 Feb;47(2):186–93.
17. Cooke CR, Kahn JM, Watkins TR, Hudson LD, Rubenfeld GD. Cost-effectiveness of Implementing Low-Tidal Volume Ventilation in Patients With Acute Lung Injury. *Chest*. 2009 Jul;136(1):79–88.
18. Baston CM, Coe NB, Guerin C, Mancebo J, Halpern S. The Cost-Effectiveness of Interventions to Increase Utilization of Prone Positioning for Severe Acute Respiratory Distress Syndrome. *Critical Care Medicine*. 2019;47(3):e198–205.
19. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. [Internet]. Ottawa: CADTH; 2017. Available from: <https://www.cadth.ca/guidelines-economic-evaluation-health-technologies-canada-4th-edition>
20. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. *BMC Med*. 2022 Jan 12;20(1):23.
21. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *JAMA*. 2016 Sep 13;316(10):1093–103.
22. Wick KD, Matthay MA, Ware LB. Pulse oximetry for the diagnosis and management of acute respiratory distress syndrome. *The Lancet Respiratory Medicine* [Internet]. 2022 Aug 29 [cited 2022 Sep 6];0(0). Available from: [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(22\)00058-3/fulltext?rss=yes](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00058-3/fulltext?rss=yes)
23. Riviello ED, Kiviri W, Twagirumugabe T, Mueller A, Banner-Goodspeed VM, Officer L, et al. Hospital Incidence and Outcomes of the Acute Respiratory Distress Syndrome Using the Kigali Modification of the Berlin Definition. *American Journal of Respiratory and Critical Care Medicine*. 2016 Jan;193(1):52–9.
24. Brown SM, Grissom CK, Moss M, Rice TW, Schoenfeld D, Hou PC, et al. Nonlinear Imputation of Pao₂/Fio₂ From Spo₂/Fio₂ Among Patients With Acute Respiratory Distress Syndrome. *Chest*. 2016 Aug;150(2):307–13.
25. Sanz F, Dean N, Dickerson J, Jones B, Knox D, Fernández-Fabrellas E, et al. Accuracy of PaO₂ /FiO₂ calculated from SpO₂ for severity assessment in ED patients with pneumonia. *Respirology*. 2015 Jul;20(5):813–8.

26. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA - Journal of the American Medical Association*. 2020 Apr;323(16):1574–81.
27. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA [Internet]*. 2020 Apr; Available from: <https://jamanetwork.com/journals/jama/fullarticle/2765184>
28. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020 Feb;395(10223):497–506.
29. Bertram MY, Lauer JA, Stenberg K, Edejer TTT. Methods for the Economic Evaluation of Health Care Interventions for Priority Setting in the Health System: An Update From WHO CHOICE. *International Journal of Health Policy and Management*. 2021 Nov 1;10(Special Issue on WHO-CHOICE Update):673–7.
30. Johnson A, Bulgarelli L, Pollard T, Horng S, Celi LA, Mark R. MIMIC-IV (version 0.4) [Internet]. *PhysioNet*; 2020. Available from: <https://doi.org/10.13026/a3wn-hq05>
31. Goldberger AL, Amaral LA, Glass L, Hausdorff JM, Ivanov PC, Mark RG, et al. PhysioBank, PhysioToolkit, PhysioNet: Components of a new research resource for complex physiologic signals. *Circulation*. 2000 Jun;101(23):E215-20.
32. Yarnell CJ, Abrams D, Baldwin MR, Brodie D, Fan E, Ferguson ND, et al. Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making? *The Lancet Respiratory Medicine*. 2021 Feb 1;9(2):207–16.
33. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan: A probabilistic programming language. *Journal of Statistical Software*. 2017 Jan;76(1):1–32.
34. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from: <https://www.r-project.org>
35. Herridge MS, Chu LM, Matte A, Tomlinson G, Chan L, Thomas C, et al. The RECOVER Program: Disability Risk Groups and 1-Year Outcome after 7 or More Days of Mechanical Ventilation. *American Journal of Respiratory and Critical Care Medicine*. 2016 Oct;194(7):831–44.
36. Guertin JR, Feeny D, Tarride JE. Age- and sex-specific Canadian utility norms, based on the 2013–2014 Canadian Community Health Survey. *CMAJ*. 2018 Feb 12;190(6):E155–61.
37. Evans J, Kobewka D, Thavorn K, D’Egídio G, Rosenberg E, Kyeremanteng K. The impact of reducing intensive care unit length of stay on hospital costs: evidence from a tertiary care hospital in Canada. *Can J Anesth/J Can Anesth*. 2018 Jun 1;65(6):627–35.
38. Canadian Institute for Health Information. Care in Canadian ICUs. Ottawa, Ontario: CIHI; 2016 p. 36.
39. Wodchis WP, Austin PC, Henry DA. A 3-year study of high-cost users of health care. *CMAJ*. 2016 Feb 16;188(3):182–8.

40. Inflation Calculator [Internet]. [cited 2023 Feb 2]. Available from: <https://www.bankofcanada.ca/rates/related/inflation-calculator/>
41. TreeAge Pro 2021 [Internet]. Williamstown, MA: TreeAge Software; Available from: <http://www.treeage.com>
42. Fenwick E, Steuten L, Knies S, Ghabri S, Basu A, Murray JF, et al. Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. *Value in Health*. 2020 Feb 1;23(2):139–50.
43. Heath A, Baio G. Calculating the Expected Value of Sample Information Using Efficient Nested Monte Carlo: A Tutorial. *Value in Health*. 2018 Nov 1;21(11):1299–304.
44. Strong M, Oakley JE, Brennan A. Estimating Multiparameter Partial Expected Value of Perfect Information from a Probabilistic Sensitivity Analysis Sample: A Nonparametric Regression Approach. *Med Decis Making*. 2014 Apr 1;34(3):311–26.
45. Strong M, Oakley JE, Brennan A, Breeze P. Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample. *Med Decis Making*. 2015 Jul;35(5):570–83.
46. Heath A, Strong M, Glynn D, Kunst N, Welton NJ, Goldhaber-Fiebert JD. Simulating Study Data to Support Expected Value of Sample Information Calculations: A Tutorial. *Med Decis Making*. 2022 Feb 1;42(2):143–55.
47. Yarnell CJ, Angriman F, Ferreyro B, Liu K, De Grooth HJ, Burry L, et al. Oxygenation Thresholds for Invasive Ventilation in Hypoxemic Respiratory Failure: A Target Trial Emulation in Two Cohorts [Internet]. Rochester, NY; 2022 [cited 2022 Dec 28]. Available from: <https://papers.ssrn.com/abstract=4276595>
48. Krishnan JK, Rajan M, Baer BR, Hoffman KL, Alshak MN, Aronson KI, et al. Assessing mortality differences across acute respiratory failure management strategies in Covid-19. *Journal of Critical Care*. 2022 Aug 1;70:154045.
49. Moore TJ, Heyward J, Anderson G, Alexander GC. Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study. *BMJ Open*. 2020 Jun 1;10(6):e038863.
50. Koffijberg H, Rothery C, Chalkidou K, Grutters J. Value of Information Choices that Influence Estimates: A Systematic Review of Prevailing Considerations. *Med Decis Making*. 2018 Oct 1;38(7):888–900.
51. Silberzahn R, Uhlmann EL, Martin DP, Anselmi P, Aust F, Awtrey E, et al. Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results. *Advances in Methods and Practices in Psychological Science*. 2018 Sep 1;1(3):337–56.
52. Sjoding MW, Dickson RP, Iwashyna TJ, Gay SE, Valley TS. Racial Bias in Pulse Oximetry Measurement. *New England Journal of Medicine*. 2020 Dec 17;383(25):2477–8.

53. Eaton Turner E, Jenks M. Cost-effectiveness analysis of the use of high-flow oxygen through nasal cannula in intensive care units in NHS England. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2018 May 4;18(3):331–7.